



REGENT™ AORTIC  
MECHANICAL HEART VALVE

**IMPLANT CONFIDENTLY.**

Information contained herein for DISTRIBUTION in Europe, Middle East and Africa ONLY.  
Check the regulatory status of the device in areas where CE marking is not the regulation in force.

  
**Abbott**


**CONFIDENTLY  
IMPLANT THE  
MOST TRUSTED  
MECHANICAL  
VALVES IN THE  
WORLD**

**NEARLY  
3 MILLION PATIENTS  
TREATED WITH ABBOTT  
MECHANICAL HEART VALVES**

**MORE THAN 1,000  
PEER-REVIEWED  
PUBLICATIONS PROVIDE  
EVIDENCE FOR ABBOTT  
MECHANICAL HEART VALVES**


**DESIGN-DRIVEN HEMODYNAMIC CONFIDENCE  
& LOW THROMBOGENICITY**

**ABBOTT MECHANICAL HEART VALVES  
LEAD THE WAY WITH A PROVEN  
BILEAFLET DESIGN THAT RESULTS IN LOW  
THROMBOGENICITY AND EXCELLENT  
PATIENT OUTCOMES.**




- Regent valve leaflets open to an 85 degree angle in systole due to their upstream positioning, enabled by unique pivot guards (shown above).<sup>3</sup>
- Strong, uniform velocities within hinge recesses aid washout of blood elements.<sup>4</sup>
- Low carbon surface area means less thrombus formation.
- Regent's orifice-to-annulus ratio (as high as 84%) ensures large EOAs and reduces Prosthesis-Patient Mismatch.<sup>5</sup>

**THE REGENT AORTIC VALVE FEATURES EXCEPTIONAL  
HEMODYNAMICS IN SMALL AORTIC ROOT PATIENTS.\*1,2**



\* Measured one year post-surgery

Information contained herein for DISTRIBUTION in Europe, Middle East and Africa ONLY.  
Check the regulatory status of the device in areas where CE marking is not the regulation in force.



**LAMINAR DOWNSTREAM FLOW THROUGH A REGENT VALVE PROVIDES PATIENTS OPTIMAL  
HEMODYNAMIC PERFORMANCE AND LOW GRADIENTS THAT MITIGATE SHEAR STRESS AND  
THROMBOGENICITY.<sup>6</sup>**

# ABBOTT ANTICOAGULATION MANAGEMENT A DEMONSTRATED WORLDWIDE HISTORY OF EXCELLENCE OVER A WIDE INR RANGE

THE REGENT AORTIC VALVE SHOWS LOW THROMBOEMBOLISM, THROMBOSIS, AND BLEEDING OVER A WIDE INR RANGE, MAKING THIS VALVE AN EXCELLENT CHOICE.

INR 1.5 ————— 2.0 ————— 2.5

## SAITO<sup>7</sup> (1.6-2.5)

Retrospective Study	950 patients, 30 years
Thromboembolism	0.56%/pt-year
Thrombosis	0.02%/pt-year
Freedom from bleeding	0.27%/pt-year



## LOWERING-IT<sup>8</sup> (1.5-2.5)

Randomized Study	44 patients*, 5 years
Thromboembolism	0.09%/pt-year
Thrombosis	0%/pt-year
Bleeding events	0.56%/pt-year



## ESCAT III<sup>9</sup> (1.6-2.1)

Randomized Study	1,137 patients**, 2 years
Thromboembolism	0%/pt-year, 0.58%/pt-year***
Bleeding events	1.07%/pt-year, 0.58%/pt-year†



## EMERY<sup>10</sup> (1.8-2.5)

Retrospective Study	2,982 patients, 25 years
Thromboembolism	1.9%/pt-year
Thrombosis	0.06%/pt-year
Freedom from bleeding	2.7%/pt-year



\*44/197 patients in the Lowering-IT study were implanted with Abbott Valves


\*\*This was further stratified into a control group, a very low INR (monitored 1x weekly), and a very low INR (monitored 2x weekly) group.

\*\*\*Thromboembolic events for VL1 and VL2 groups are listed together, respectively

†Bleeding events for VL1 and VL2 groups are listed together, respectively

Information contained herein for DISTRIBUTION in Europe, Middle East and Africa ONLY.  
Check the regulatory status of the device in areas where CE marking is not the regulation in force.

# REGENT GIVES YOU IMPLANTABILITY OPTIONS. MAKE THE BEST DECISION FOR YOUR PATIENTS.




Low valve implant height helps ensure coronary ostia clearance.



Replica sizing with the 907 sizer gives you confidence that you are using the most appropriately sized valve.

Two distinct cuff types provide you with different options.



Information contained herein for DISTRIBUTION in Europe, Middle East and Africa ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.



## REGENT™ VALVE AND ACCESSORIES ORDERING GUIDE

### Regent™ Valves

SIZE (MM)	STANDARD CUFF	FLEXCUFF™ <sup>4</sup>
17	17AGN-751	17AGFN-756
19	19AGN-751	19AGFN-756
21	21AGN-751	21AGFN-756
23	23AGN-751	23AGFN-756
25	25AGN-751	25AGFN-756
27	27AGN-751	27AGFN-756
29	29AGN-751	29AGFN-756

<sup>4</sup>All sizes may not be available in your region. Contact your Abbott representative for details.

### Mechanical Valve Sizer and Accessories

MODEL NO.	DESCRIPTION
907	SJM Regent™ sizer set contains 17–29 mm valve sizers and valve holder handle model 905-HH
905	Universal sizer set contains 17–33 mm valve sizers and valve holder handle model 905-HH
905-RHH	Rigid valve holder handle

### REFERENCES

- Okamura, Homare, et al. "Is the threshold for postoperative prosthesis-patient mismatch the same for all prostheses?" *Surgery today* 43.8 (2013): 871-876.
- Regent PMA Supplement
- Shipkowitz, T., et al. "Evaluation technique for bileaflet mechanical valves." *The Journal of heart valve disease* 11.2 (2002): 275-282.
- Jun, Brian H., Neelakantan Saikrishnan, and Ajit P. Yoganathan. "Micro particle image velocimetry measurements of steady diastolic leakage flow in the hinge of a St. Jude Medical® regent™ mechanical heart valve." *Annals of biomedical engineering* 42.3 (2014): 526-540.
- Abbott Internal Document 90423960
- Alemu, Yared, and Danny Bluestein. "Flow-induced platelet activation and damage accumulation in a mechanical heart valve: numerical studies." *Artificial organs* 31.9 (2007): 677-688.
- Saito, Satoshi, et al. "Bileaflet mechanical valve replacement: an assessment of outcomes with 30 years of follow-up." *Interactive cardiovascular and thoracic surgery* 23.4 (2016): 599-607.
- Torella, Michele, et al. "LOWERING the INTensity of oral anticoagulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial." *American heart journal* 160.1 (2010): 171-178.
- Koertke, Heinrich, et al. "Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement." *The Annals of thoracic surgery* 90.5 (2010): 1487-1493.
- Emery, Robert W., et al. "The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement." *The Annals of thoracic surgery* 79.3 (2005): 776-782.

Information contained herein for DISTRIBUTION in Europe, Middle East and Africa ONLY.  
Check the regulatory status of the device in areas where CE marking is not the regulation in force.

**CAUTION:** This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use provided inside the product carton (when available), at [eifu.abbottvascular.com](http://eifu.abbottvascular.com) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

**Abbott Vascular International BVBA**

Park Lane, Culliganlaan 2b, 1831 Diegem, Belgium  
[www.Cardiovascular.Abbott](http://www.Cardiovascular.Abbott)

<sup>™</sup>Indicates a trademark of the Abbott group of companies.

‡ Indicates a third party trademark, which is property of its respective owner.

©2019 Abbott. All rights reserved 9-EH-1-9113-01 02-2019

